



HAL
open science

Perforin level in CD4 T cells from patients with systemic lupus erythematosus

Anna Kozłowska, Pawel Hrycaj, Jan K. Łącki, Pawel Piotr Jagodziński

► **To cite this version:**

Anna Kozłowska, Pawel Hrycaj, Jan K. Łącki, Pawel Piotr Jagodziński. Perforin level in CD4 T cells from patients with systemic lupus erythematosus. *Rheumatology International*, 2010, 30 (12), pp.1627-1633. 10.1007/s00296-009-1329-1 . hal-00568323

HAL Id: hal-00568323

<https://hal.science/hal-00568323>

Submitted on 23 Feb 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Perforin level in CD4⁺ T cells from patients with systemic lupus erythematosus

Anna Kozłowska¹, Paweł Hrycaj², Jan K. Łacki³, Paweł P. Jagodziński¹

¹Department of Biochemistry and Molecular Biology,

²Department of Rheumatology and Clinical Immunology
Poznań University of Medical Sciences, Poznań, Poland

³Institute of Rheumatology, Warsaw Poland

Running heading: perforin expression in CD4⁺ T cells

*Corresponding author: Dr Paweł P. Jagodziński, Department of Biochemistry and Molecular Biology, University of Medical Sciences, 6 Święcickiego St., 60-781 Poznań, Poland

Tel: (48 61) 854 65 13, Fax: (48 61) 854 65 10, E-mail: pjagodzi@am.poznan.pl

Summary

CD4⁺ T cells from patients with systemic lupus erythematosus (SLE) exhibit increased expression of various proteins contributing to defective function of CD4⁺ T cells.

We evaluated the transcript and protein levels of perforin (PRF1) in CD4⁺ T cells from SLE patients (n=41) and healthy individuals (n=34). The CD4⁺ T cells were obtained by a positive biomagnetic separation system. The amounts of mRNA were determined by reverse transcription and real-time quantitative PCR. The protein levels in the CD4⁺ T cells were evaluated by western blotting analysis. We observed significantly higher levels of PRF1 protein (p= 0.013) in SLE CD4⁺ T cells than in controls. There was no significant increase in PRF1 transcript levels (p=0.908) in CD4⁺ T cells from SLE patients as compared to healthy individuals. Moreover, we did not observe a correlation between PRF1 transcript and protein levels in SLE CD4⁺ T cells and disease activity expressed by the SLEDAI scale.

We confirmed previous observations that demonstrated higher levels of PRF1 protein in CD4⁺ T cells from SLE patients. However, we did not find a correlation between PRF1 transcripts and proteins in CD4⁺ T cells and SLE disease activity.

Introduction

Systemic lupus erythematosus (SLE) is a progressive, systemic autoimmune disease with multi-organ engagement, characterized by an immune response directed against self antigens [1]. The SLE target tissues include skin, kidneys, joints, and the central nervous system [1]. Exposure to certain chemicals, drugs, food, and infectious factors also contributes to SLE incidence [2, 3]. Moreover, there is an evident genetic background in the incidence of this autoimmune disorder [4-6].

Three major processes are considered in the initiation, development and clinical manifestation of SLE; they include an increase in the plasma concentration of nuclear auto-antigens, T cell-dependent stimulation of B cells for the biosynthesis of antinuclear antibodies (Ab), and organ damage mediated by anti-double stranded DNA Ab and immune complexes [7-9].

Increased apoptosis and reduced removal of apoptotic cells lead to the formation of necrotic cells, which are source of nuclear antigens for biosynthesis of Ab [10, 11]. Cytotoxic T lymphocytes involved in killing other host cells may be significant producers of preferential and selective autoantigens [12]. T cells from lupus patients may kill autologous monocytes/macrophages, and may thus contribute to both increase of the amount of antigenic apoptotic material and the reduction of its clearance [13, 14].

It has been concluded that defective helper functions of CD4⁺ T cells can contribute to improper activation of B cells and autoantibody production [15-18]. Despite CD4⁺ T cells function mainly as helper cells, a subpopulation of these cells also functions in an effector capacity by carrying out cytotoxicity in a peptide-specific and MHC class II-restricted mode [19]. The latter function of CD4⁺ T cells mainly depends on granzyme B and perforin-1 (PRF1) exocytosis rather than on CD95-ligand binding to CD95 [19]. An increased presence of cytotoxic CD4⁺ T cells has been associated with vascular damage and incidence of various

autoimmune diseases, including SLE [20-24]. The overexpression of PRF1 in both CD4⁺ T and CD8⁺ T cells from peripheral mononuclear cells (PBMC), and its role in SLE pathogenesis has been demonstrated [24, 25]. Kaplan *et al.* (2004), employing staining of PBMC and flow cytometry analysis, showed a significant correlation between percentage of PRF1⁺ CD4⁺ T cells in PBMC and disease activity in SLE patients [24].

We decided to examine mRNA and protein levels in whole CD4⁺ T cells from a larger group of SLE patients (n=41) and healthy individuals (n=34) than those demonstrated by Kaplan *et al.* [24]. Whole CD4⁺ T cells from whole peripheral blood were isolated by positive biomagnetic separation. Isolated mRNA and proteins from CD4⁺ T cells were used for reverse transcription, real-time quantitative PCR and western blotting analysis. Subsequently we determined whether there exist correlations between increased PRF1 transcript and protein levels in CD4⁺ T cells and SLE disease activity.

Materials and methods

Patients and controls

Forty-one consecutive SLE patients seen between September 2006 and October 2008 at the Institute of Rheumatology in Warsaw and Department of Rheumatology and Clinical Immunology at the Poznań University of Medical Sciences, Poland were included in the present study (Table 1). Patients fulfilled at least 4 of the American College of Rheumatology 1982 revised criteria for SLE [26, 27]. Disease activity for the SLE patients was assessed using the SLEDAI scale (Table 1) [28]. Twenty-four patients were treated by prednisone. Seventeen patients were receiving methylprednisone, and ten patients were also receiving hydroxychloroquine. In order to reduce the effect of corticosteroid medication on our results, patients who were on prednisone or methylprednisone were asked not to take this medication for at least 24 h before drawing blood. Clinical manifestations of SLE in the patient group

included central nervous system (22%), vascular (20%), renal (42%), musculoskeletal (29%), serosal (20%), dermal (34%), immunologic (85%), febrile (8%), and hematologic (29%) components.

Both patients and control groups were of Polish Caucasian origin. The control group included thirty-four healthy individuals (32 women and 2 men). The mean age of healthy individuals was 36.6 ± 9.6 years. The protocol of the investigation was approved by the Local Ethical Committee of Poznań University of Medical Sciences. Written informed consent was signed by all participating individuals.

Antibodies

Rabbit polyclonal anti- PRF1 Ab (H-315), goat anti-rabbit horseradish peroxidase (HRP)-conjugated Ab and anti-actin HRP-conjugated Ab (clone I-19) were provided by Santa Cruz Biotechnology (Santa Cruz, CA).

CD4⁺ T cell isolation

The CD4⁺ cells were isolated from a 10 ml whole peripheral blood sample taken from each patient, employing the positive biomagnetic separation technique using DETACHaBEADS[®] M-450 CD4 from Dynal Biotech (Lake Success, NY) (29). The flow cytometry analysis (n=29) indicated $95.6 \% \pm 1.4$ purity of CD4⁺ T cells.

Real-time quantitative PCR (RQ-PCR) analysis of PRF1 transcript levels in CD4⁺ T cells

Total RNA was isolated according to the method of Chomczyński and Sacchi [29]. RNA samples were treated with DNase I, and 1 µg RNA was reverse-transcribed into cDNA using oligo-dT primers. RQ-PCR was conducted in a Light Cycler real-time PCR detection system from Roche Diagnostics GmbH, (Mannheim, Germany) using SYBR[®] Green I as detection dye. Target cDNA was quantified using relative quantification method with a calibrator. The calibrator was prepared as a cDNA mix from all SLE and control samples and

consecutive dilutions were used to create a standard curve as described in Relative Quantification Manual Roche Diagnostics GmbH, (Mannheim, Germany). For amplification, 2 µl of cDNA solution was added to 18 µl of QuantiTect[®] SYBER[®] Green PCR Master Mix QIAGEN GmbH (Hilden, Germany) and primers. The quantity of PRF1 transcript in each sample was standardized by human mitochondrial ribosomal protein L19 (hMRPL19).

The PRF1 cDNA 170 bp amplicon was amplified employing the pair of primers: 5' CACCCTCTGTGAAAATGCCCTAC3' (forward) and 5' TCCAGTCGTTGCGGATGCTAC3' (reverse).

The hMRPL19 cDNA 171bp amplicon was amplified using primers:

5' ACTTTATAATCCTCGGGTC 3' (forward) and 5' ACTTTCAGCTCATTAACAG 3' (reverse). These PRF1 and hMRPL19 primers were designed based on sequences ENST00000373209 and ENST00000393909 respectively, located in Ensembl Genome Browser (www.ensembl.org). The PRF1 mRNA levels were expressed as multiples of these cDNA concentrations in the calibrator.

Western blot analysis of PRF1 protein contents in CD4⁺ T cells.

CD4⁺ lymphocytes were lysed in lysis buffer, and ten micrograms of protein was resuspended in sample buffer. The proteins were separated on 10% Tris-glycine gel using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membrane. Immunodetection was performed with rabbit polyclonal anti-PRF1, and HRP-conjugated goat anti-rabbit Ab. The membranes were reblotted with anti-actin HRP-conjugated Ab to equalize protein loading of the lanes. To detect the examined protein from the same blot membrane we used stripping buffer. Bands were revealed using SuperSignal West Femto Maximum Sensitivity Substrate Pierce (Rockford, IL). The quantities of western blot-detected PRF1 and β-actin proteins were determined based on the band optical density.

The band densitometry readings were normalized to β -actin loading control to calculate the PRF1-to β -actin optical density ratio.

Statistical analysis

Statistical analysis was conducted using StatSoft, Inc. (2001). STATISTICA (data analysis software system), version 6. www.statsoft.com. The significance of differences between groups was determined using nonparametric Mann-Whitney test. Correlations between PRF1 expression and disease activity as defined by the SLEDAI scale were assessed by Spearman analysis.

Results

PRF1 transcript and protein levels in CD4⁺ T cells from SLE patients and controls

To compare PRF1 transcript and protein levels in CD4⁺ T cells from SLE patients and controls, we used RQ-PCR and western blotting analysis, respectively. There was no significant increase in PRF1 transcript level in SLE CD4⁺ T cells as compared to controls (p=0.908) (Figure 1A and Table 2). However, we observed significantly higher content of PRF1 protein in CD4⁺ T cells from SLE patients as compared to healthy individuals (p=0.013) (Figures 1B, C, and Table 2). There was no correlation between PRF1 transcript and protein levels in SLE CD4⁺ T cells and disease activity defined by the SLEDAI scale (Figures 2A and 2B). We also did not find a relationship between patients' age, disease duration, drug treatment, and **type of individual organ manifestation** with PRF1 transcript and protein levels in SLE CD4⁺ T cells (data not shown).

Discussion

It has previously been demonstrated that there is an increased expression many proteins responsible for defective function of CD4⁺ T cells [15,16, 18]. These proteins include signal molecules, transcription factors, components of TCR/CD3 complex, costimulatory proteins, cytokines and molecules involved in the cytotoxic response [15,16, 18].

PRF1 protein, with molecular mass of 60 to 75 kD, is a pore-forming molecule presented in cytotoxic lymphocytes, which execute immune mediated cell lysis [30]. The *PRF1* gene is expressed primarily in NK cells and effector CD8⁺ T cells [31, 32]. *PRF1* is also expressed in a subpopulation of cytotoxic CD4⁺ T cells, which may combat various pathogens (33-39). An increased number of cytotoxic CD4⁺ T cells has been observed in patients with multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and acute coronary syndromes [20-23].

Lu *et al* (2003) demonstrated that DNA methylation and chromatin structure regulate *PRF1* expression in T cells [40]. Moreover, Kaplan *et al.* (2004) showed that DNA methylation inhibitors increased *PRF1* expression in CD4⁺ T cells. This increase in *PRF1* transcription in CD4⁺ T cells was due to demethylation of a DNA region, which is hypomethylated in primary CD8⁺ T cells expressing *PRF1* [24]. Kaplan *et al.* (2004) also indicated that increased *PRF1* transcription in CD4⁺ T cells from SLE patients was related to demethylation of this DNA region [24]. Recently, Luo *et al.* (2009) disclosed that DNA demethylation at the *PRF1* locus is responsible for *PRF1* overexpression in CD4⁺ T cells from patients with subacute cutaneous lupus erythematosus [41].

We observed significantly higher levels of PRF1 protein in SLE CD4⁺ T cells than in healthy individuals. Our findings are consistent with Kaplan *et al.* (2004), who demonstrated a significant increase in PRF1 protein levels in SLE patients [24]. They also indicated that

aberrant PRF1 protein levels in SLE CD4⁺ T cells may contribute to killing of autologous monocytes [24].

We also found higher PRF1 transcript levels in SLE CD4⁺ T cells than in controls, but this difference was not statistically significant and did not correlate with disease activity. Although PRF1 protein level was higher in SLE CD4⁺ T cells than in controls, it also did not correlate with disease activity. Our findings suggest that an increased PRF1 protein content in SLE CD4⁺ T cells does not perpetuate disease activity in our investigated group.

Kaplan *et al.* (2004) observed that CD4⁺ T cells from patients with active, but not inactive, lupus exhibited increased PRF1 transcript levels in CD4⁺ T cells [24]. Using flow cytometry analysis, they also demonstrated that the increase in PRF1 protein contents in SLE CD4⁺ T cells was correlated to disease activity expressed by the SLEDAI scale [29]. These discrepancies between our observations and those of Kaplan *et al.* may result from the application of different methods in the determination of PRF1 protein levels in CD4⁺ T cells to establish correlation with disease activity.

The cytotoxic/effector CD4⁺ T cells make up a small amount of the whole circulating CD4⁺ T population [42]. These cells constitute the subset of CD45R0⁺CD27⁻ activated CD4⁺ T cells, which are formed during differentiation of naive CD45RA⁺CCR7⁺ T cells [42, 43]. Therefore, our analysis, conducted on the whole CD4⁺ T cell population after immune magnetic enrichment, may underestimate PRF1 transcript and protein levels in cytotoxic/effector CD4⁺ T cells. This may be responsible for the discrepancies observed between our results and those of Kaplan *et al.* [24]. These differences can also be due to varied genetics factors associated with the distinct racial structure of the examined groups or/and an exposure to disparate environmental factors contributing to SLE in these populations [3,4].

Our study confirmed previous observations that demonstrated increased PRF1 protein contents in CD4⁺ T cells from SLE patients. However, we did not find a correlation between PRF1 protein and transcript levels in CD4⁺ T cells and SLE disease activity. Therefore our results require verification in groups of SLE patients in other cohorts.

Acknowledgements

Supported by grant No. N N402 2424 33 from Polish Ministry of Scientific Research and Information Technology. We would like to acknowledge Dr. Margarita Lianeri for her assistance.

References

1. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR (2001) Systemic lupus erythematosus. *Lancet* 357:1027–1032.
2. Jönsen A, Bengtsson AA, Nived O, Truedsson L, Sturfelt G (2007) Gene-environment interactions in the aetiology of systemic lupus erythematosus. *Autoimmunity* 40: 613-617.
3. Love LA (1994) New environmental agents associated with lupus-like disorders. *Lupus* 3:467-471
4. Wong M, Tsao BP (2006) Current topics in human SLE genetics. *Springer Semin Immunopathol* .: 28: 97-107.
5. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant PV, Ballinger DG, Kosoy R, Demirci FY, Kamboh MI, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantapää-Dahlqvist S, Petri M, Manzi S, Seldin MF, Rönnblom L, Syvänen AC, Criswell LA, Gregersen PK, Behrens TW (2008) Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. *N Engl J Med* 358: 900-909.
6. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD, Nath SK, Guthridge JM, Cobb BL, Mirel DB, Marion MC, Williams AH, Divers J, Wang W, Frank SG, Namjou B, Gabriel SB, Lee AT, Gregersen PK, Behrens TW, Taylor KE, Fernando M, Zidovetzki R, Gaffney PM, Edberg JC, Rioux JD, Ojwang JO, James JA, Merrill JT, Gilkeson GS, Seldin MF, Yin H, Baechler EC, Li QZ, Wakeland EK, Bruner GR, Kaufman KM, Kelly JA (2008) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXX, KIAA1542 and other loci. *Nat Genet* 40: 204-210
7. Quigg RJ (2004) Complement and autoimmune glomerular diseases. *Curr Dir Autoimmun* 7: 165-180
8. Pirner K, Rascu A, Nurnberg W, Rubbert A, Kalden JR, Manger B. (1994) Evidence for direct anti-heparin-sulphate reactivity in sera of SLE patients. *Rheumatol Int* 14: 169-174
9. Nakajima M, Nakajima A, Kayagaki N, Honda M, Yagita H, Okumura K. (1997) Expression of Fas ligand and its receptor in cutaneous lupus: implication in tissue injury. *Clin Immunol Immunopathol*. 83: 223-229
10. Utz PJ, Anderson P (1998) Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. *Arthritis Rheum* 41:1152–1160.
11. Rosen A, Casciola-Rosen L (1999) Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. *Cell Death Differ* 6:6–12.
12. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A (1999) Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. *J Exp Med* 190:815–826.

13. Richardson BC, Strahler JR, Pivrotto TS, Quddus J, Bayliss GE, Gross LA, O'Rourke KS, Powers D, Hanash SM, Johnson MA. (1992) Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. *Arthritis Rheum.* 35: 647-62
14. Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, McCune WJ, Richardson BC (2002) The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. *J. Immunol.* 169:6020-6029
15. Crispín JC, Tsokos GC (2008) Novel molecular targets in the treatment of systemic lupus erythematosus. *Autoimmun Rev* 7:256-261.
16. Krishnan S, Farber DL, Tsokos GC (2003) T cell rewiring in differentiation and disease. *J Immunol* 171:3325-3331.
17. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM. (2003) B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. *Arthritis Rheum* 48:3475-3486.
18. Zhou Y, Lu Q (2008) DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. *Autoimmun Rev* 7:376-383
19. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, Easterbrook P, Grey P, Smith D, McMichael AJ, Cooper DA, Rowland-Jones SL, Kelleher AD (2002) Characterization of CD4(+) CTLs ex vivo. *J Immunol* 2002, 168:5954-5958.
20. Markovic-Plese S, Cortese I, Wandinger KP, McFarland HF, Martin R (2001) CD4+CD28^S costimulation-independent T cells in multiple sclerosis. *J Clin Invest* 108:1185-1194.
21. Fasth AE, Snir O, Johansson AA, Nordmark B, Rahbar A, Af KE, Bjorkstrom NK, Ulfgren AK, van Vollenhoven RF, Malmstrom V, Trollmo C (2007) Skewed distribution of proinflammatory CD4+CD28^{null} T cells in rheumatoid arthritis. *Arthritis Res Ther* 9:R87.
22. Kobayashi T, Okamoto S, Iwakami Y, Nakazawa A, Hisamatsu T, Chinen H, Kamada N, Imai T, Goto H, Hibi T (2007) Exclusive increase of CX3CR1+CD28^SCD4⁺ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. *Inflamm Bowel Dis* 13:837-846.
23. Liuzzo G, Biasucci LM, Trotta G, Brugaletta S, Pinnelli M, Digianuario G, Rizzello V, Rebuzzi AG, Rumi C, Maseri A, Crea F (2007) Unusual CD4+CD28^{null} T lymphocytes and recurrence of acute coronary events. *J Am Coll Cardiol* 50:1450-1458
24. Kaplan MJ, Lu Q, Wu A, Attwood J, Richardson B (2004) Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4⁺ lupus T cells. *J Immunol* 172:3652-3661.
25. Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF (2005) Increase in activated CD8⁺ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. *Arthritis Rheum* 52:201-211.
26. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 25:1271-1277.

27. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 40:1725.
28. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum* 35:630-640.
29. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162:156-159.
30. Podack ER, Lowrey DM, Lichtenheld M, Olsen KJ, Aebischer T, Binder D, Rupp F, Hengartner H (1988) Structure, function and expression of murine and human perforin 1 (P1). *Immun. Rev.* 103:203-211
31. Podack ER, Hengartner H, Lichtenheld MG (1991). A central role of perforin in cytotoxicity? *Annu. Rev. Immunol* 9:129-157
32. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, van Lier RA (1997). Phenotypic and functional separation of memory and effector human CD8⁺ T cells. *J. Exp. Med.* 186:1407- 1418
33. Zheng CF, Ma LL, Jones GJ, Gill MJ, Krensky AM, Kubes P, Mody CH (2007) Cytotoxic CD4⁺ T cells use granulysin to kill *Cryptococcus neoformans*, and activation of this pathway is defective in HIV patients. *Blood* 109:2049-2057.
34. Saez-Borderias A, Guma M, Angulo A, Bellosillo B, Pende D, Lopez-Botet M (2006) Expression and function of NKG2D in CD4⁺ T cells specific for human cytomegalovirus. *Eur J Immunol* 36:3198-3206.
35. Haigh TA, Lin X, Jia H, Hui EP, Chan AT, Rickinson AB, Taylor GS (2008) EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4⁺ cytotoxic T cell recognition of EBV-transformed B cell lines. *J Immunol* 180:1643-1654.
36. Zhou W, Sharma M, Martinez J, Srivastava T, Diamond DJ, Knowles W, Lacey SF (2007) Functional characterization of BK virus specific CD4⁺ T cells with cytotoxic potential in seropositive adults. *Viral Immunol* 20:379-388.
37. Milikan JC, Kinchington PR, Baarsma GS, Kuijpers RW, Osterhaus AD, Verjans GM (2007) Identification of viral antigens recognized by ocular infiltrating T cells from patients with varicella zoster virus-induced uveitis. *Invest Ophthalmol Vis Sci* 48:3689-3697.
38. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, Heiken H, Kuhlmann B, Kaiser T, Bozkaya H, Tillmann HL, Bozdayi AM, Manns MP, Wedemeyer H (2006) Cytotoxic CD4 T cells in viral hepatitis. *J Viral Hepat* 13:505-514.
39. Silva CL, Lowrie DB (2000) Identification and characterization of murine cytotoxic T cells that kill *Mycobacterium tuberculosis*. *Infect Immun* 68:3269-3274.
40. Lu Q, Wu A, Ray D, Deng C, Attwood J, Hanash S, Pipkin M, Lichtenheld M, Richardson B (2003) DNA methylation and chromatin structure regulate T cell perforin gene expression. *J Immunol.* 170:5124-5132.

41. Luo Y, Zhang X, Zhao M, Lu Q (2009) DNA demethylation of the perforin promoter in CD4(+) T cells from patients with subacute cutaneous lupus erythematosus. *J Dermatol Sci* doi:10.1016/j.jdermsci.2009.06.010
42. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, Easterbrook P, Grey P, Smith D, McMichael AJ, Cooper DA, Rowland-Jones SL, Kelleher AD . (2002) Characterization of CD4(+) CTLs ex vivo. *J Immunol.* 168: 5954-5958.
43. De Jong R, Brouwer M, Hooibrink B, Van der Pouw-Kraan T, Miedema F, Van Lier RA (1992) The CD27- subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. *Eur J Immunol.* 22: 993-999.

FIGURE LEGENDS

Fig.1. PRF1 transcript (A) and protein (B) levels and representative picture of western blot analysis (C) in CD4⁺ T cells from SLE patients and controls.

The CD4⁺ T cells were isolated from peripheral blood by positive biomagnetic separation technique, and were immediately used for RNA and protein isolation. Total RNA was reverse-transcribed, and cDNAs were investigated by RQ-PCR relative quantification analysis. The PRF1 mRNA levels were corrected to the amount of hMRLP19. The amounts of PRF1 mRNA were expressed as the natural logarithm of multiples of these cDNA copies in the calibrator. Proteins were separated using SDS-PAGE, transferred, and the membranes were immunoblotted respectively with primary anti-PRF1 Ab and secondary Ab. The membranes were reblotted with anti-β-actin HRP-conjugated Ab. The amount of western blot-detected PRF1 proteins was presented as the natural logarithm of PRF1-to β-actin band optical density ratio. (○) and (●) represent transcript levels in controls and SLE patients, respectively. *Median (range), ND-non detected.

Fig. 2. The correlation between PRF1 transcript (**A**) and protein (**B**) in CD4⁺ T cells and clinical activity of SLE scored in the SLEDAI scale.

The CD4⁺ T cells were used for RNA and protein isolation. Total RNA was reverse-transcribed into cDNAs and investigated by RQ-PCR relative quantification analysis. PRF1 mRNA levels were corrected to hMRLP19 levels. The quantities of PRF1 mRNA were expressed as the natural logarithm of multiples of these cDNA copies in the calibrator. The CD4⁺ T cell proteins were separated using SDS-PAGE, transferred, and the membranes were immunoblotted respectively with primary anti-PRF1 Ab and secondary Ab. The membranes were reblotted with anti- β -actin HRP-conjugated Ab. The amount of western blot-detected PRF1 was presented as the natural logarithm of PRF1-to β -actin band optical densities ratio. r-Spearman correlation coefficient.

Table 1. Demographic, and disease activity of SLE patients

Patients Number	41
Sex (Female/Male)	39/2
Mean (\pm SD) of age at diagnosis (years)	36.2 \pm 13.3
SLEDAI scores	Patients number
0-5	13
6-10	11
11-15	4
>16	13

Table 2. PRF1 transcript and protein levels in CD4⁺ T cells from SLE patients and controls

	SLE		Controls		p
	Median (range)	Mean (\pm SD)	Median (range)	Mean (\pm SD)	
PRF1	1.02 (0.06-11.14) ^a	1.66 \pm 2.23 ^a	1.04 (0.10-4.75) ^a	1.34 \pm 1.24 ^a	0.908 ^a
	0.67 (ND-4.50) ^b	0.87 \pm 1.04 ^b	0.66 (ND-2.84) ^b	0.37 \pm 0.67 ^b	0.013 ^b


^aThe target mRNA levels were corrected to the amount of hMRLP19

cDNA and expressed as multiplicity of these


cDNA copies in calibrator. ^bThe amount of western blot detected proteins was presented as the PRF1 to β -actin band optical density ratio. ^cMann-Whitney test, ND-non detected

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41


A



B



C




1
2
3
4
5
6
7
8
9

Fig. 1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

A



B

Fig. 2